pharma news today glp-1 obesity A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio As GLP-1 drugs for obesity

Inhibin, beta A regulates the transforming growth factor-beta pathway to promote malignant biological behaviour in colorectal cancer

4.7 Pregnancy-related effects Although type 2 diabetes and obesity have been effectively treated with GLP-1 receptor agonists, their role in pregnancy and breastfeeding has been a controversial debate due to potential risks to the mothers health and fetal outcomes (87)

Cell 187(15):38293853 [DOI] [PMC free article] [PubMed] [Google Scholar] Lambson JE, Flegal SC, Johnson AR (2023) Administration errors of compounded semaglutide reported to a poison control centerCase series

GLP-1 agonists directly counter this

Patients with type 2 diabetes in the SURPASS clinical trials lost between 12lb and 25lb on average